These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

648 related items for PubMed ID: 27098525

  • 21. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials.
    Russell-Jones D, Gall MA, Niemeyer M, Diamant M, Del Prato S.
    Nutr Metab Cardiovasc Dis; 2015 Oct; 25(10):898-905. PubMed ID: 26232910
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial.
    Davies MJ, Gross JL, Ono Y, Sasaki T, Bantwal G, Gall MA, Niemeyer M, Seino H, BEGIN BB T1 Study Group.
    Diabetes Obes Metab; 2014 Oct; 16(10):922-30. PubMed ID: 24702700
    [Abstract] [Full Text] [Related]

  • 25. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
    Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN, Kvist K, Norwood P.
    JAMA; 2017 Jul 04; 318(1):45-56. PubMed ID: 28672317
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.
    Liu M, Gu W, Chen L, Li Y, Kuang H, Du J, Alvarez A, Lauand F, Souhami E, Zhang J, Xu W, Du Q, Mu Y, SoliD trial investigators.
    Diabetes Obes Metab; 2024 Sep 04; 26(9):3791-3800. PubMed ID: 38922731
    [Abstract] [Full Text] [Related]

  • 30. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.
    Cannon AJ, Bargiota A, Billings L, Hunt B, Leiter LA, Malkin S, Mocarski M, Ranthe MF, Schiffman A, Doshi A.
    J Manag Care Spec Pharm; 2020 Feb 04; 26(2):143-153. PubMed ID: 31856636
    [Abstract] [Full Text] [Related]

  • 31. Comparative efficiency and safety of insulin degludec/aspart with insulin glargine in type 2 diabetes: a meta-analysis of randomized controlled trials.
    Long T, Lin JT, Lin MH, Wu QL, Lai JM, Li SZ, Zhou ZC, Zeng JY, Huang JS, Zeng CP, Lai YM.
    Endocr J; 2022 Aug 29; 69(8):959-969. PubMed ID: 35431280
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre, randomised, crossover study.
    Nakamura T, Sakaguchi K, So A, Nakajima S, Takabe M, Komada H, Okuno Y, Hirota Y, Nakamura T, Iida K, Kajikawa M, Nagata M, Ogawa W, Seino S.
    Diabetologia; 2015 Sep 29; 58(9):2013-9. PubMed ID: 26044206
    [Abstract] [Full Text] [Related]

  • 34. Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes.
    Rodbard HW, Cariou B, Zinman B, Handelsman Y, Wolden ML, Rana A, Mathieu C.
    Diabetes Obes Metab; 2014 Sep 29; 16(9):869-72. PubMed ID: 24495158
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used.
    Norwood P, Chen R, Jaeckel E, Lingvay I, Jarlov H, Lehmann L, Heller S.
    Diabetes Obes Metab; 2017 Nov 29; 19(11):1562-1569. PubMed ID: 28417535
    [Abstract] [Full Text] [Related]

  • 40. Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial.
    Billings LK, Doshi A, Gouet D, Oviedo A, Rodbard HW, Tentolouris N, Grøn R, Halladin N, Jodar E.
    Diabetes Care; 2018 May 29; 41(5):1009-1016. PubMed ID: 29483185
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.